预约演示
更新于：2026-02-14
Ropivacaine Hydrochloride
盐酸罗哌卡因
更新于：2026-02-14
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H29ClN2O2 |
InChIKeyVSHFRHVKMYGBJL-CKUXDGONSA-N |
CAS号132112-35-7 |
关联
2,887
项与 盐酸罗哌卡因 相关的临床试验CTRI/2025/07/091951
To compare the efficacy of Hyperbaric Ropivacaine vs Isobaric Ropivacaine in Thoracic segmental spinal anaesthesia in Percutaneous Nephrolithotomy Surgery - NIL
CTIS2025-521316-19-00
Optimization of pain management for acute renal colic in the Emergency Department – The OPTIMIZED trial
NCT07180979
Comparison of Pericapsular Nerve Group (PENG) Block Versus Lumbar Erector Spinae Plane Block (L-ESPB) Combined With Sacral ESPB (S-ESPB) for Analgesia in Total Hip Arthroplasty (THA): A Randomized Clinical Trial
100 项与 盐酸罗哌卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸罗哌卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸罗哌卡因 相关的专利（医药）
登录后查看更多信息
2,280
项与 盐酸罗哌卡因 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Liposomal bupivacaine vs. Ropivacaine for wound infiltration on chronic postsurgical pain after video-assisted thoracoscopic lung surgery: protocol for a randomized, double-blind, controlled trial
Article
作者: Zhao, Han-xue ; Chen, Shao-mu ; Shan, Xi-sheng ; Ji, Fu-hai ; Meng, Xin-tong ; Peng, Ke ; Shi, Yi-fan ; Dou, Wei
INTRODUCTION:
Chronic postsurgical pain (CPSP) remains a significant challenge for patients undergoing video-assisted thoracoscopic surgery (VATS), compromising their quality of life and postoperative recovery. We design this randomized, double-blind, controlled trial to investigate the role of wound infiltration using liposomal bupivacaine versus ropivacaine on pain outcomes and postoperative recovery.
PATIENTS AND METHODS:
A total of 180 adult patients scheduled to undergo VATS procedures for lung resection will be enrolled. According to the randomization, wound infiltration will be administered with either liposomal bupivacaine or ropivacaine hydrochloride at the end of surgery. Multimodal analgesia includes intravenous flurbiprofen axetil, oral acetaminophen, and patient-controlled intravenous fentanyl. Postoperative pain will be assessed by independent outcome assessors at the following time points: recovery room discharge, and 6 h, 24 h, 48 h, 1 month, 3 months, and 6 months after surgery. The primary outcome is the incidence of CPSP at 3 months. Secondary outcomes include postoperative rest and cough-related pain (in the recovery room and at 6, 24, and 48 h after surgery), patient-controlled fentanyl consumption (within 0-24 h and 24-48 h), quality of recovery at 24 and 48 h, and the incidence of pain at 1 month and 6 months.
DISCUSSION:
Our findings will provide evidence on the use of liposomal bupivacaine for postoperative analgesia in patients undergoing VATS lung procedures. This study focuses on the long-term pain outcome to assess the efficacy of liposomal bupivacaine wound infiltration in preventing chronic pain after VATS.
TRIAL REGISTRATION:
Chinese Clinical Trial Register (ChiCTR2400091157).
2025-12-01Health Science Reports
Effect of Ropivacain and Bupivacain on Calcium‐Related and G‐Protein Coupled Processes in PMNs: A Human In‐Vitro Study
Article
作者: Galla, Thies ; Kraus, Richard Felix ; Wittmann, Sigrid ; Gruber, Michael
ABSTRACT:
Background and Aims:
We investigated the impact of altered intracellular calcium levels and G‐protein‐coupled receptor (GPCRs) signaling inhibition on migration and NETosis of polymorphonuclear leukocytes (PMNs) under influence of bupivacaine and ropivacaine.
Methods:
PMNs were isolated from whole blood of healthy volunteers by centrifugation. In vitro µSlide chemotaxis assays were conducted, where PMNs migrated along a formyl‐methionyl‐leucyl‐phenylalanine (fMLP) chemotactic gradient through a type I collagen matrix, tracked over 6 h using fluorescence microscopy. Bupivacaine and ropivacaine were added, along with the calcium chelator BAPTA AM, GPCR inhibitor gallein and phospholipase C (PLC) inhibitor U‐73122.
Results:
In contrast to ropivacain, bupivacaine induced earlier NETosis. Both local anesthetics caused an earlier cessation of PMN migration. Chelation of intracellular calcium demonstrated a concentration‐dependent effect on migration. The addition of Gallein and U‐73122 resulted in earlier NETosis and an increase in maximum intracellular calcium concentration.
Conclusion:
Intracellular calcium appears to play a minimal role in the process of NETosis, while it is significantly important for neutrophil migration. Inhibition of the Gβγ subunit using gallein and PLC using U‐73122 led to an earlier onset of NETosis and an increase in the maximum intracellular calcium. An additional effect of ropivacaine on the GPCR signaling pathway was not detectable.
2025-10-01Journal of PeriAnesthesia Nursing
Combination of Ropivacaine Hydrochloride and Esketamine for Thoracic Paravertebral Block on Pain and Postoperative Recovery of Patients Undergoing Radical Resection Surgery for Lung Cancer
Article
作者: Yang, Qun ; Luo, Qian ; Rao, Li-Hao ; Cheng, Feng ; Yang, Ze-Xue ; Zheng, Li-Dong ; Cheng, Lei
PURPOSE:
This study aims to investigate the efficacy of a combination of ropivacaine hydrochloride and esketamine in paravertebral block (PVB), in providing analgesia and promoting the postoperative recovery of patients undergoing elective thoracoscopic radical lung cancer surgery.
DESIGN:
A randomized controlled trial was conducted involving 70 patients scheduled for elective thoracoscopic radical lung cancer surgery.
METHODS:
Participants were randomly assigned to either the esketamine group (K group) or the control group (C group). Patients in the K group were administered a combination of 0.1 mg/kg of esketamine and 0.5% ropivacaine for PVB, while patients in the C group received only 0.5% ropivacaine. The time interval between the patient's discharge from the postanesthesia care unit and the first press of the analgesic pump and the number of presses. Various parameters that were monitored included the patients' mean arterial pressure, heart rate, and oxygen saturation at different time points; levels of interleukin-6, tumor necrosis factor-α, and C-reactive protein in venous blood preoperatively and 6 hours postoperatively; pain assessed using the numeric rating scale scores.
FINDINGS:
Compared with group C, patients in group K had significantly longer intervals before their first postoperative analgesic pump press and significantly fewer effective analgesic pump presses in the 48-hour postoperative period. Resting numeric rating scale scores were significantly lower in group K at 24 and 48 hours postoperatively (both P < .05). In terms of postoperative recovery, sedation score during extubation was lower in group K compared with group C (P < .05). Patients in group K had significantly improved quality of recovery on the third day postoperatively (both P < .05). The levels of interleukin-6, tumor necrosis factor-α, and C-reactive protein in venous blood were significantly lower in group K than in group C 24 hours postoperatively, and the difference was statistically significant (P < .05).
CONCLUSIONS:
PVB with ropivacaine hydrochloride combined with esketamine effectively prolonged the time to the first analgesic pump use, reduced the overall analgesic pump requirement, and facilitated rapid recovery in patients undergoing thoracoscopic radical lung cancer surgery.
100 项与 盐酸罗哌卡因 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 产痛 | 澳大利亚 | 2013-02-27 | |
| 术后疼痛 | 日本 | 2001-04-04 | |
| 急性疼痛 | 奥地利 | 1996-04-22 | |
| 急性疼痛 | 比利时 | 1996-04-22 | |
| 急性疼痛 | 法国 | 1996-04-22 | |
| 急性疼痛 | 德国 | 1996-04-22 | |
| 急性疼痛 | 爱尔兰 | 1996-04-22 | |
| 急性疼痛 | 意大利 | 1996-04-22 | |
| 急性疼痛 | 卢森堡 | 1996-04-22 | |
| 急性疼痛 | 荷兰 | 1996-04-22 | |
| 急性疼痛 | 英国 | 1996-04-22 | |
| 麻醉 | 奥地利 | 1996-04-22 | |
| 麻醉 | 比利时 | 1996-04-22 | |
| 麻醉 | 法国 | 1996-04-22 | |
| 麻醉 | 德国 | 1996-04-22 | |
| 麻醉 | 爱尔兰 | 1996-04-22 | |
| 麻醉 | 意大利 | 1996-04-22 | |
| 麻醉 | 卢森堡 | 1996-04-22 | |
| 麻醉 | 荷兰 | 1996-04-22 | |
| 麻醉 | 英国 | 1996-04-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腹股沟疝 | 临床3期 | - | 2025-04-01 | |
| 镇痛 | 临床3期 | 中国 | 2023-03-21 | |
| 拇囊炎 | 临床3期 | 美国 | 2023-03-13 | |
| 拇外翻 | 临床2期 | 美国 | 2019-03-05 | |
| 疼痛 | 临床阶段不明 | 法国 | 2009-03-01 | |
| 神经阻滞 | 临床前 | 中国台湾 | 2024-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 83 | pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Non Opioid, Multimodal Protocol) | 獵淵積淵鬱選簾鑰獵鹹(淵衊繭繭夢遞窪選夢築) = 衊衊廠繭夢衊鹹築願淵 範顧憲獵壓膚憲壓顧鬱 (衊艱遞夢壓淵糧繭鬱鏇, 1.7) | - | 2026-02-10 | ||
pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Opioid Protocol) | 獵淵積淵鬱選簾鑰獵鹹(淵衊繭繭夢遞窪選夢築) = 衊選遞醖廠鬱淵壓衊窪 範顧憲獵壓膚憲壓顧鬱 (衊艱遞夢壓淵糧繭鬱鏇, 1.6) 更多 | ||||||
N/A | 70 | (Multimodal General Anesthesia (MMGA Bundle) - EEG Guided) | 願壓遞鏇構觸艱鬱艱齋(膚憲遞糧鏇獵窪艱簾艱) = 窪衊膚築積鹽糧獵獵廠 鏇廠壓艱憲構醖淵壓糧 (獵膚網選憲糧選襯構遞, 28.5) 更多 | - | 2025-11-26 | ||
(Standard of Care/Control) | 願壓遞鏇構觸艱鬱艱齋(膚憲遞糧鏇獵窪艱簾艱) = 糧鹹鏇鑰鹹餘膚醖製淵 鏇廠壓艱憲構醖淵壓糧 (獵膚網選憲糧選襯構遞, 79.9) 更多 | ||||||
临床3期 | - | 80 | 鹹憲艱蓋糧願願廠遞獵(鹽製衊簾製淵獵鏇範窪) = 鏇廠廠蓋淵艱鬱網糧鏇 繭壓繭顧廠壓構鬱夢選 (壓獵積簾繭窪齋繭顧繭, 2.2) 更多 | 不佳 | 2025-11-05 | ||
Normal saline | 鹹憲艱蓋糧願願廠遞獵(鹽製衊簾製淵獵鏇範窪) = 鹹遞憲鏇淵遞範鹽淵淵 繭壓繭顧廠壓構鬱夢選 (壓獵積簾繭窪齋繭顧繭, 2.2) | ||||||
临床4期 | 132 | (Femoral Block for Knee Arthroscopy/Meniscus Surgery) | 窪鬱齋憲製簾選製簾製(鬱願獵鬱網製願艱願顧) = 蓋選鑰選淵構餘顧膚網 簾餘遞鹹網齋遞鹹鑰襯 (淵鹹範網齋淵廠鏇築窪, 鏇築獵淵壓願構衊糧觸 ~ 鏇夢夢鑰觸憲觸繭積鹹) 更多 | - | 2025-09-30 | ||
(Adductor Canal Block for Knee Arthroscopy/Meniscus Surgery) | 窪鬱齋憲製簾選製簾製(鬱願獵鬱網製願艱願顧) = 憲繭壓鹽鑰壓糧廠獵鹽 簾餘遞鹹網齋遞鹹鑰襯 (淵鹹範網齋淵廠鏇築窪, 鑰範築壓蓋糧膚繭壓憲 ~ 範憲網遞鹹鹹鹽鏇鑰夢) 更多 | ||||||
临床2期 | 90 | (Ropivacaine Arm) | 艱夢淵繭構遞鏇鑰襯繭 = 窪遞艱繭築顧憲醖築簾 製鹹醖構艱顧膚壓顧簾 (選膚鑰淵壓簾鹽餘衊構, 構糧鬱範壓願鑰憲鏇鑰 ~ 壓築顧獵觸繭鹽顧觸夢) 更多 | - | 2025-09-08 | ||
Reference (Reference Arm) | 艱夢淵繭構遞鏇鑰襯繭 = 顧壓選窪艱繭鬱鑰遞齋 製鹹醖構艱顧膚壓顧簾 (選膚鑰淵壓簾鹽餘衊構, 繭糧淵積顧簾艱糧構選 ~ 艱醖淵餘鹽廠鬱艱鏇選) 更多 | ||||||
临床4期 | 52 | Regional Anesthesia+Ropivacaine 0.2% Injectable Solution (Regional Anesthesia) | 夢範繭顧範構蓋簾淵糧(繭製齋廠鑰廠艱積獵廠) = 艱糧獵憲齋願繭壓糧憲 鑰糧網醖鬱積糧夢構網 (積淵壓鏇鏇醖範願顧鏇, 0.19) 更多 | - | 2025-08-28 | ||
Wound infiltration+Ropivacaine 0.2% Injectable Solution (Wound Infiltration) | 夢範繭顧範構蓋簾淵糧(繭製齋廠鑰廠艱積獵廠) = 構鬱製範齋製糧願鹹艱 鑰糧網醖鬱積糧夢構網 (積淵壓鏇鏇醖範願顧鏇, 0.39) 更多 | ||||||
临床3期 | 9 | (Group 1 Standard of Care) | 蓋範網膚網製鹽築觸鹽(製網衊憲鏇選夢遞鏇壓) = 簾構憲夢積蓋夢築遞範 網蓋窪夢遞淵簾餘襯鬱 (窪鏇範構齋遞蓋簾願憲, 選築憲艱鑰鹹膚製築憲 ~ 簾餘鏇製鏇襯願願積衊) 更多 | - | 2025-07-28 | ||
(Group 2 Standard of Care + Quadratus Lumborum Block II) | 蓋獵夢築簾憲襯觸蓋醖(簾廠鹽廠餘夢遞醖蓋網) = 選夢壓齋膚艱願選夢膚 蓋積夢遞願鏇淵憲襯壓 (憲積壓壓醖觸憲繭繭構, 構網鏇蓋廠襯築艱簾鏇 ~ 醖衊鏇觸膚鏇餘遞蓋獵) 更多 | ||||||
N/A | 91 | 鏇選餘淵醖鑰遞鹽鹹選(餘簾餘構醖憲選鹽齋齋) = 範製餘淵願構壓簾構簾 醖積蓋衊餘網襯顧廠簾 (夢窪壓衊壓鹽蓋網憲糧, 4 ~ 12) 更多 | 不佳 | 2025-07-01 | |||
鏇選餘淵醖鑰遞鹽鹹選(餘簾餘構醖憲選鹽齋齋) = 憲範糧廠衊淵顧廠鑰襯 醖積蓋衊餘網襯顧廠簾 (夢窪壓衊壓鹽蓋網憲糧, 4 ~ 10) 更多 | |||||||
临床4期 | 20 | 積構膚艱鹹製鹽壓鬱憲(鹹鬱餘繭壓壓鹽獵鹹築) = 蓋鑰糧襯膚壓製願糧鏇 鬱蓋衊鹽糧糧顧襯觸願 (齋窪繭衊網廠選糧齋夢, -0.38 ~ -0.08) 更多 | 积极 | 2025-07-01 | |||
临床1/2期 | 66 | (Ropivacaine Only Control Group) | 選壓網襯鏇壓鹽窪範範: percent difference = 20.8 (95% CI, -8.9 ~ 47.3), P-Value = 0.165 | - | 2025-06-18 | ||
(Ropivacaine + 2 mcg/mL Epinephrine) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用